Dylann Cohn-Emery | Authors


Primary End Point of Improved DFS Not Met With Adjuvant Canakinumab in NSCLC

September 12, 2022

Adjuvant treatment with canakinumab did not meet the disease-free survival primary end point in patients with completely resected non–small cell lung cancer versus placebo, nor did subgroup analyses show statistically significant differences in DFS, according to results from the phase 3 CANOPY-A trial presented at ESMO Congress 2022.